Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TG-1000 Phase 1 Safety and PK Study in Healthy Volunteers
NCT04495322Phase 1Completed
- Sponsor
- TaiGen Biotechnology Co., Ltd.
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TG-1000 in influenza (8 arms), sponsored by TaiGen Biotechnology Co., Ltd. Primary endpoints: Number of subjects of treatment-emergent adverse events at 8 days, Number of subjects of Significant Abnormal Vital Signs Findings at 8 days and 4 more. Started Jul 2020; status: completed.
02
Drugs
TG-1000
03
Conditions
influenza
Beyond the preview
Go deeper on NCT04495322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04495322.